• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Study of 2-Bromo-1-(1-methyl-1H-pyrrol-2-yl)-Ethanone (CAS: 65438-97-3)

The compound 2-bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone (CAS: 65438-97-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications in drug discovery and development. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

Recent studies have highlighted the role of 2-bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone as a key intermediate in the synthesis of heterocyclic compounds, which are widely used in the development of pharmaceuticals. Its unique structural features, including the bromo and pyrrole moieties, make it a valuable building block for the construction of more complex molecules with potential biological activity. Researchers have successfully employed this compound in the synthesis of novel kinase inhibitors and antimicrobial agents, demonstrating its broad utility in medicinal chemistry.

In a groundbreaking study published in the Journal of Medicinal Chemistry, scientists investigated the anti-cancer properties of derivatives synthesized from 2-bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone. The results indicated that certain derivatives exhibited potent inhibitory effects against specific cancer cell lines, with IC50 values in the nanomolar range. These findings suggest that this compound could serve as a promising scaffold for the development of new anti-cancer therapeutics.

Another area of active research involves the use of 2-bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone in the development of antimicrobial agents. A recent study published in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound displayed significant activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, highlighting its potential as a lead compound for novel antibiotic development.

From a synthetic chemistry perspective, advancements have been made in optimizing the production of 2-bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone. A team of researchers recently developed a more efficient and environmentally friendly synthesis route, reducing the use of hazardous reagents and improving overall yield. This progress is particularly important for scaling up production for potential pharmaceutical applications.

Looking forward, the unique properties of 2-bromo-1-(1-methyl-1H-pyrrol-2-yl)-ethanone position it as a compound of significant interest in drug discovery. Current research efforts are focused on exploring its potential in targeting various disease pathways, including inflammation and neurodegenerative disorders. As more studies emerge, this compound may prove to be a versatile tool in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)